Shelly Karuna

2.7k total citations
29 papers, 273 citations indexed

About

Shelly Karuna is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, Shelly Karuna has authored 29 papers receiving a total of 273 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 15 papers in Virology and 6 papers in Molecular Biology. Recurrent topics in Shelly Karuna's work include HIV Research and Treatment (15 papers), HIV/AIDS Research and Interventions (9 papers) and vaccines and immunoinformatics approaches (5 papers). Shelly Karuna is often cited by papers focused on HIV Research and Treatment (15 papers), HIV/AIDS Research and Interventions (9 papers) and vaccines and immunoinformatics approaches (5 papers). Shelly Karuna collaborates with scholars based in United States, Peru and South Africa. Shelly Karuna's co-authors include Lawrence Corey, M. Juliana McElrath, Michele P. Andrasik, Gail Broder, Peter B. Gilbert, Carmela Ganoza, Kenneth H. Mayer, Youyi Fong, Javier R. Lama and Maria P. Lemos and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and PLoS ONE.

In The Last Decade

Shelly Karuna

27 papers receiving 266 citations

Peers

Countries citing papers authored by Shelly Karuna

Since Specialization

Citations

This map shows the geographic impact of Shelly Karuna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shelly Karuna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shelly Karuna more than expected).

Fields of papers citing papers by Shelly Karuna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shelly Karuna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shelly Karuna. The network helps show where Shelly Karuna may publish in the future.

Co-authorship network of co-authors of Shelly Karuna

This figure shows the co-authorship network connecting the top 25 collaborators of Shelly Karuna. A scholar is included among the top collaborators of Shelly Karuna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shelly Karuna. Shelly Karuna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Accelerating vaccine development in Africa: lessons from HIV research 2025 ·The Lancet ·Nicaise Ndembi, Shelly Karuna, Jessica Cowden, Alberto Cagigi, (unknown), Amber Moodley, Julie A. Ake, Sandhya Vasan, Nelson Michael, Jérôme H. Kim	1
2	Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1–uninfected adult participants in the US 2023 ·Vaccine ·Hong‐Van Tieu, Shelly Karuna, Yunda Huang, Magdalena E. Sobieszczyk, Hua Zheng, Georgia D. Tomaras, David C. Montefiori, (unknown), (unknown), Kristen W. Cohen, (unknown), (unknown), Jack Heptinstall, Kelly E. Seaton, Sheetal Sawant, (unknown), Michael Pensiero, Lawrence Corey, Katharine J. Bar	0
3	Application of the SLAPNAP statistical learning tool to broadly neutralizing antibody HIV prevention research 2023 ·iScience ·Brian D. Williamson, Craig A. Magaret, Shelly Karuna, Lindsay N. Carpp, Huub C. Gelderblom, Yunda Huang, David Benkeser, Peter B. Gilbert	2
4	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation 2021 ·Scientific Reports ·Yunda Huang, Oleg Borisov, Jia Jin Kee, Lindsay N. Carpp, Terri Wrin, (unknown), Marcella Sarzotti‐Kelsoe, Charlene McDanal, Amanda Eaton, Rolando Pajón, John Hural, Christine M. Posavad, Katherine Gill, Shelly Karuna, Lawrence Corey, M. Juliana McElrath, Peter B. Gilbert, Christos J. Petropoulos, David C. Montefiori	20
5	Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features 2019 ·PLoS Computational Biology ·Craig A. Magaret, David Benkeser, Brian D. Williamson, Bhavesh Borate, Lindsay N. Carpp, Ivelin S. Georgiev, Ian Setliff, Adam S. Dingens, Noah Simon, Marco Carone, Christopher E. Simpkins, David C. Montefiori, Galit Alter, Wen‐Han Yu, Michal Juraska, Paul T. Edlefsen, Shelly Karuna, Nyaradzo Mgodi, (unknown), Peter B. Gilbert	27
6	Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination 2019 ·PLoS ONE ·Jacob A. Cram, Andrew Fioré-Gartland, Sujatha Srinivasan, Shelly Karuna, Giuseppe Pantaleo, Georgia D. Tomaras, David N. Fredricks, James G. Kublin	16
7	A descriptive analysis of transgender participants in phase 1-2a trials of the HIV Vaccine Trials Network (HVTN) in the United States and Peru 2019 ·Vaccine ·Michele P. Andrasik, Doug Grove, Gail Broder, Hyman Scott, Mary Allen, Shelly Karuna	3
8	Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials 2018 ·Human Vaccines & Immunotherapeutics ·Yunda Huang, Shelly Karuna, Lindsay N. Carpp, Daniel B. Reeves, Amarendra Pegu, Kelly E. Seaton, Kenneth H. Mayer, Joshua T. Schiffer, John R. Mascola, Peter B. Gilbert	17
9	Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or Circumcision in a Cohort Study of MSM at Risk of HIV Infection 2016 ·PLoS ONE ·Javier R. Lama, Shelly Karuna, Shannon Grant, Edith Swann, Carmela Ganoza, Patricia Segura-Medina, Silvia M. Montano, (unknown), Stephen C. De Rosa, Susan Buchbinder, Jorge Sánchez, M. Juliana McElrath, Maria P. Lemos, (unknown)	3
10	In men at risk of HIV infection, IgM, IgG1, IgG3, and IgA reach the human foreskin epidermis 2015 ·Mucosal Immunology ·Maria P. Lemos, Shelly Karuna, Gregory J. Mize, Youyi Fong, Silvia M. Montano, Carmela Ganoza, Javier R. Lama, Jorge Sánchez, M. Juliana McElrath	10
11	HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial 2014 ·Journal of Clinical Investigation ·Pierre‐Alexandre Bart, Yunda Huang, Shelly Karuna, (unknown), Julien Gaillard, Nidhi Kochar, Xiaoying Shen, Mary Allen, S.-W Ding, John Hural, Hua-Xin Liao, Barton F. Haynes, Barney S. Graham, Peter B. Gilbert, M. Juliana McElrath, David C. Montefiori, Georgia D. Tomaras, Giuseppe Pantaleo, Nicole Frahm	18
12	Inclusion of Transgender and Gender Non-conforming Communities in Preventive HIV Vaccine Research at the HIV Vaccine Trials Network (HVTN) 2014 ·AIDS Research and Human Retroviruses ·Gail Broder, Michele P. Andrasik, Shelly Karuna, (unknown)	0
13	CD8 ⁺ T-cell Mediated HIV Inhibition after Vaccination with a DNA/Recombinant Ad5 (rAd5) HIV Vaccine Is Similar to that Seen in Treated HIV Infection 2014 ·AIDS Research and Human Retroviruses ·Nicole Frahm, (unknown), Stephen C. De Rosa, Christina Ochsenbauer, Shelly Karuna, Magdalena E. Sobieszczyk, Scott Hammer, Edith Swann, Barney S. Graham, Peter B. Gilbert, (unknown), (unknown)	1
14	Implementing Good Participatory Practice (GPP) in HVTN505 - The HIV Vaccine Trials Network (HVTN) Experience 2014 ·AIDS Research and Human Retroviruses ·Gail Broder, James Maynard, Shelly Karuna, Chuka Anude, Magda Sobieszczyk, Scott M. Hammer, (unknown)	1
15	The Inner Foreskin of Healthy Males at Risk of HIV Infection Harbors Epithelial CD4+ CCR5+ Cells and Has Features of an Inflamed Epidermal Barrier 2014 ·PLoS ONE ·Maria P. Lemos, Javier R. Lama, Shelly Karuna, Youyi Fong, Silvia M. Montano, Carmela Ganoza, Raphaël Gottardo, Jorge Sánchez, M. Juliana McElrath	26
16	Use of placebos in Phase 1 preventive HIV vaccine clinical trials 2014 ·Vaccine ·Yunda Huang, Shelly Karuna, Holly Janes, Nicole Frahm, Martha Nason, Paul T. Edlefsen, James G. Kublin, Lawrence Corey, M. Juliana McElrath, Peter B. Gilbert	1
17	Transgender Participants in the HIV Vaccine Trial Network's HVTN 505 Trial: A Descriptive and Comparative Analysis 2014 ·AIDS Research and Human Retroviruses ·Shelly Karuna, Doug Grove, Gail Broder, Chuka Anude, Scott M. Hammer, Magda Sobieszczyk, Michele P. Andrasik, (unknown)	1
18	Intentions to Use Preexposure Prophylaxis Among Current Phase 2B Preventive HIV-1 Vaccine Efficacy Trial Participants 2013 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jonathan D. Fuchs, Magdalena E. Sobieszczyk, Tamra Madenwald, Doug Grove, Shelly Karuna, Michele P. Andrasik, Adam Sherwat, Gail Broder, Kenneth H. Mayer, Beryl A. Koblin, Scott Hammer	15
19	Behavioral risk assessment in HIV Vaccine Trials Network (HVTN) clinical trials: A qualitative study exploring HVTN staff perspectives 2013 ·Vaccine ·Michele P. Andrasik, Shelly Karuna, (unknown), Beryl A. Koblin, (unknown)	5
20	rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses 2012 ·Retrovirology ·Pierre‐Alexandre Bart, Yulan Huang, Nicole Frahm, Shelly Karuna, Mary Allen, (unknown), (unknown), Julien Gaillard, (unknown), Giuseppe Pantaleo	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact